Join        Login             Stock Quote

Warner Chilcott (WCRX) Q4 Profit Rises 38 Pct, Beats Expectations

 February 22, 2013 08:04 AM

(By Balachander) Warner Chilcott Plc (NASDAQ: WCRX), the women healthcare company, posted a 38 percent increase in net income for the fourth quarter amid lower revenue of its postmenopausal osteoporosis treatement. Results topped market expectations.

GAAP earnings increased to $124 million or $0.49 per share for the fourth quarter from $90 million or $0.36 per share in the comparable period of last year.

Adjusted cash net income (CNI) was 91 cents a share for the three months ended Dec. 31, 2012.

Revenue fell 5 percent to $612 million as revenue of postmenopausal osteoporosis treatement ACTONEL declined 42 percent and decreases in the U.S. oral bisphosphonate market.

[Related -Merger Arbitrage Mondays – June 3, 2013]

Wall Street analysts, on average, expected earnings of $0.73 per share on revenue to drop 12.50 percent to $565.2 million.

Selling, general and administrative fell 16 percent, while cost of sales increased 18 percent.

Looking ahead for the full year, the Ireland-based company had earlier this month said it expects adjusted CNI per share in the range of $3.20 to $3.30, on revenue between $2.30 billion and $2.40 billion. Analysts expect earnings of $3.32 per share on revenue of $2.35 billion.

The company's other principal products include ATELVIA to treat postmenopausal osteoporosis; LOESTRIN 24 FE and LO LOESTRIN FE, which are oral contraceptives for the prevention of pregnancy; ESTRACE cream, a vaginal cream for the treatment of vaginal and vulvar atrophy.

WCRX shares, which have been trading in the 52-week range of $10.85 to $23.28, closed at $13.76 on Thursday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imagePick a Valid Strategy, Stick With It

I’m not going to argue for any particular strategy here. My main point is this: every valid strategy is read on...

article imageHow to Prepare For A Correction Without Missing Out On Upside Potential

Recent market commentary is starting to remind me of the periods in 2000 and 2008 just before the bottom read on...

article imageBritain’s Boom Can Still Zoom

Don’t overthink the disconnect between strong UK GDP and wobbly UK stocks. Economic fundamentals should win read on...

article imageA Serious Red Flag

Stocks have stayed largely in reverse gear in the last week following weaker-than-expected earnings reports read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.